International Journal of Drug Delivery Technology
Volume 14, Issue 2

Nanosuspensions in Breast Cancer Therapy: A Comprehensive Overview

Sebastine1, Mohamed Zerein Fathima2*

1School of Pharmaceutical Sciences, Vels Institute of Science, Technology & Advanced Studies, Chennai, Tamil Nadu, India.

2Department of Pharmaceutical Chemistry and Analysis, School of Pharmaceutical Sciences, Vels Institute of Science, Technology & Advanced Studies, Chennai, Tamil Nadu, India. 

Received: 18th January, 2024; Revised: 20th March, 2024; Accepted: 10th May, 2024; Available Online: 25th June, 2024 

ABSTRACT

Nanosuspensions offer a promising avenue for enhancing breast cancer treatment through improved drug delivery, solubility, and targeting. These colloidal dispersions contain submicron drug particles, significantly increasing surface area and enhancing drug solubility and dissolution rates. This improvement can lead to increased drug bioavailability, enabling lower doses and reduced side effects. It is also possible to engineer nanosuspensions so that they are controlled-release drugs, providing sustained therapeutic levels at the tumor site. Nanosuspensions facilitate targeted drug delivery, which is one of their key advantages. In order to minimize systemic toxicity, nanosuspensions contain targeting ligands or antibodies that adhere to the surface of nanoparticles in order to deliver drugs specifically to breast cancer cells. The nanosuspension platform also allows a combination therapy approach to be used, allowing multiple drugs to be delivered simultaneously in order to achieve synergistic effects and combat drug resistance. Nanosuspension treatments can be beneficial both therapeutically and for imaging and diagnostic purposes. Using nanoparticles labeled with imaging agents, it is possible to visualize tumors and monitor treatment responses. Nanosuspensions may reduce side effects associated with traditional chemotherapy by improving drug targeting and reducing systemic exposure. A nanosuspension represents a promising treatment option for breast cancer. Nanosuspensions must be fully exploited for their full potential to improve outcomes and quality of life for patients.

Keywords: Nanosuspension, Breast cancer, Drug delivery, Solubility, Targeting, Controlled release, Combination therapy, Imaging, Diagnostics.

International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.2.73

How to cite this article: Sebastine, Fathima MZ. Nanosuspensions in Breast Cancer Therapy: A Comprehensive Overview. International Journal of Drug Delivery Technology. 2024;14(2):1090-1098.

REFERENCES

  1. Gradishar WJ, Anderson BO, Balassanian R, et al. Breast Cancer, NCCN Clinical Practice Guidelines in Journal of the National Comprehensive Cancer Network. 2020; 18(4):452-478.
  2. Ismael G, Hegg R, Muehlbauer S, et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. The Lancet Oncology. 2012; 13(9):869-878.
  3. Tevaarwerk AJ, Wang M, Zhao F, et al. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor- positive breast cancer (E-3193, INT-0142): A trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology. 2015; 33(33):3938-3948.
  4. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised The Lancet. 2015; 386(10001):1341-1352.
  5. Ahmed, S., et al. Selection of Stabilizers and Surfactants for Nanoparticle Formulations: A Comprehensive Advanced Materials Interfaces, 2019; 6(13): 1900590.
  6. Das, A., et al. Optimization of Nanosuspension Formulation by Design of Experiment (DOE) Current Drug Delivery, 2018; 15(9): 1307-1321.
  7. Zhang, , et al. Impact of Formulation Variables on the Particle Size and Stability of Nanosuspensions. Journal of Pharmaceutical Sciences, 2020; 109(3): 1123-1134.
  8. Sharma, P., et al. Characterization of Nanosuspensions. Journal of Nanoscience and Nanotechnology, 2017; 17(2): 1225-1235.
  9. Singh, V., et al. Zeta Potential as a Measure of Nanoparticle Stability. Langmuir, 2018; 34(38), 11145-11152.
  10. Wang, , et al. Blood Sampling Techniques for Pharmacokinetic Analysis of Nanoparticles. Journal of Pharmaceutical Analysis, 2019; 9(4): 223-229
  11. Gupta, A., et al. Therapeutic Efficacy of Nanosuspensions in Breast Cancer Models. Journal of Controlled Release, 2020; 327: 571-584.
  12. Müller, R., et al. Drug Loading Efficiency of Nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2016; 108: 284-290.
  13. Li, Q., et al. Pharmacokinetics of Nanosuspensions. Journal of Pharmaceutical Sciences, 2018;107(8): 2041-2054.
  14. Jain, A., et al. Dissolution Studies of Nanoparticles. Journal of Pharmaceutical Sciences, 2019; 108(6):1985-1995.
  15. Chen, , et al. Release Kinetics and Mechanism of Nanoparticles. International Journal of Pharmaceutics, 2021; 599: 120457.
  16. Agrawal, , et al. Stability Studies of Nanoparticles. Journal of Controlled Release, 2020; 324: 601-614.
  17. Rana, S., et al. Biocompatibility Studies of Nanoparticles. Journal of Biomedical Materials Research Part A, 2019; 107(11): 2431-2441.
  18. Patel, , et al. Toxicity Assessment of Nanoparticles in Animal Models. Nanotoxicology, 2021; 15(1): 48-65.
  19. Khan I, Iqbal M, Awan U, Shah Y, Ahmad W, Shah A, et al. Formulation development and in-vitro evaluation of docetaxel nanosuspension for intravenous Curr Drug Deliv. 2016; 13(8):1328-1338.
  20. Hu B, Chen J, Ma P, Wang J, Zhang Z, Yu Q, et al. Paclitaxel- loaded poly( N-vinylpyrrolidone)-b-poly(ɛ-caprolactone) nanoparticles: Preparation and antitumor activity in-vivo. J Biomater Appl. 2017; 32(9):1232-1242.
  21. Shen Y, Zhang H, Zhang J, Li Y, He Q, Gao H, et al. A targeted and pH-responsive fulvestrant nanosuspension for Sustained release of fulvestrant in treatment of estrogen receptor-positive breast cancer. Pharmaceutics. 2018; 10(4):199.
  22. Song Q, Wu J, Zhou L, Zhang J, Wang Y, Chen T, et al. pH-sensitive nanoparticles for doxorubicin delivery for intracellular imaging and anticancer Int J Nanomedicine. 2019; 14:7265-7278.
  23. Xiao B, Ma L, Merlin Nanoparticle-mediated co-delivery of chemotherapeutic agent and siRNA for combination cancer therapy. Expert Opin Drug Deliv. 2018; 15(8):757-772.
  24. Li Y, He H, Jia X, Lu W, Lou J, Wei Y. A dual-targeting nanosuspension drug delivery system for bone metastatic breast cancer: Synthesis and biological Int J Nanomedicine. 2017; 12:5779-5792.
  25. Wang H, Zhao Y, Wu Y, Hu Y, Nan K, Nie G, et al. Enhanced anti-breast cancer activity of a paclitaxel nanosuspension in combination with a “nanotransporter” derived from fish oil. Nanoscale. 2020; 12(14):7735-7747.
  26. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology. 2007; 2(12):751-760.
  27. Taurin S, Nehoff H, Greish K. Anticancer nanomedicine and tumor vascular permeability; where is the missing link. Journal of Controlled Release. 2012; 164(3):265-275.
  28. Danhier F, Feron O, Préat To exploit the t umor microenvironment: Passive and active tumor targeting of nanocarriers for anticancer drug delivery. Journal of Controlled Release. 2010; 148(2):135-146.
  29. Kunjachan S, Rychlik B, Storm G, Kiessling F, Lammers T. Multidrug resistance: Physiological principles and nanomedical solutions. Advanced Drug Delivery Reviews. 2013; 65(13- 14):1852-1865.
  30. Anselmo AC, Mitragotri Nanoparticles in the clinic: An update. Bioengineering & Translational Medicine. 2019;4(3):e10143.